XILIO THERAPEUTICS INC. - COMMON STOCK

0,8920

22-ноября-24 15:44:58

15 мин. задержка

Акции

-0,0280

-3,04%

Сегодняшний диапазон

0,8700 - 0,9400

ISIN

N/A

Источник

NASDAQ

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

07 ноя 2024 08:15:00 Источник Nasdaq GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

07 ноя 2024 08:05:00 Источник Nasdaq GlobeNewswire
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

30 окт 2024 08:01:00 Источник Nasdaq GlobeNewswire
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

04 окт 2024 08:05:00 Источник Nasdaq GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 окт 2024 15:15:03 Источник Nasdaq GlobeNewswire
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

28 авг 2024 15:01:00 Источник Nasdaq GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

08 авг 2024 06:30:00 Источник Nasdaq GlobeNewswire
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors

13 июн 2024 15:05:00 Источник Nasdaq GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

14 май 2024 06:30:00 Источник Nasdaq GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

01 апр 2024 15:05:00 Источник Nasdaq GlobeNewswire
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

28 мар 2024 06:05:00 Источник Nasdaq GlobeNewswire
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

28 мар 2024 06:00:00 Источник Nasdaq GlobeNewswire
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference

28 фев 2024 15:01:00 Источник Nasdaq GlobeNewswire
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference

31 янв 2024 15:01:00 Источник Nasdaq GlobeNewswire
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies

08 янв 2024 06:30:00 Источник Nasdaq GlobeNewswire
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

07 дек 2023 06:30:00 Источник Nasdaq GlobeNewswire
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

09 ноя 2023 15:01:00 Источник Nasdaq GlobeNewswire
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors

03 ноя 2023 11:00:00 Источник Nasdaq GlobeNewswire
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting

31 окт 2023 08:15:00 Источник Nasdaq GlobeNewswire
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

27 сен 2023 16:02:48 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.